Table 2. Long-term toxicity after PRRT with either 90Y-octreotide or 177Lu-octreotate in GEP-NETs.
| Agent | Patients | Follow-up (months) | Renal toxicity | MDS | Acute leukemia | Reference |
|---|---|---|---|---|---|---|
| 90Y-octreotide | 40 | 19 | 10% Grade 1 | 0 | 0 | (16) |
| 39 | 6 | 3% Grade 2 | 0 | 0 | (26) | |
| 58 | 18 | 3% Grade 4 | 1 | 0 | (27) | |
| 1,109 | 23 | 9.2% Grade 3/4 | 1 | 1 | (19) | |
| 358 | 30 | 2.8% | 7 (1.95%) | 5 (1.4%) | (42) | |
| 177Lu-octreotate | 504 | 19 | 0.4% Grade 4 | 3 | 0 | (20) |
| 51 | 29 | 24% Grade 1 | 0 | 0 | (21) | |
| 74 | 21 | 1.3% Grade 3/4 | 3 | 0 | (43,44) | |
| 290 | 30 | 0% | 6 (2.06%) | 2 (0.69%) | (42) |
PRRT, peptide receptor radionuclide therapy; GEP-NET, gastroenteropancreatic neuroendocrine tumor; MDS, myelodysplastic syndrome.